Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 12-Month High - Here's Why

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP hit a new 52-week high during trading on Tuesday . The stock traded as high as $12.53 and last traded at $12.22, with a volume of 2298248 shares trading hands. The stock had previously closed at $12.27.

Analyst Upgrades and Downgrades

Several analysts have commented on AUPH shares. Royal Bank Of Canada lifted their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. HC Wainwright restated a "buy" rating and set a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $12.00.

Aurinia Pharmaceuticals Price Performance

The firm has a market cap of $1.59 billion, a price-to-earnings ratio of 28.09 and a beta of 1.23. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. The company's 50-day moving average price is $9.39 and its 200-day moving average price is $8.50.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). The firm had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Insiders Place Their Bets

In related news, Director Kevin Tang purchased 200,000 shares of the company's stock in a transaction on Tuesday, August 5th. The shares were bought at an average cost of $11.68 per share, for a total transaction of $2,336,000.00. Following the completion of the purchase, the director directly owned 11,329,500 shares of the company's stock, valued at approximately $132,328,560. This trade represents a 1.80% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have purchased a total of 1,300,000 shares of company stock valued at $13,590,000 over the last 90 days. 12.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Marex Group plc acquired a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth $1,143,000. State of Wyoming acquired a new stake in Aurinia Pharmaceuticals in the second quarter valued at $240,000. Hudson Bay Capital Management LP lifted its holdings in Aurinia Pharmaceuticals by 4.0% in the second quarter. Hudson Bay Capital Management LP now owns 104,000 shares of the biotechnology company's stock valued at $881,000 after acquiring an additional 4,000 shares during the period. Nomura Holdings Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth $176,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Aurinia Pharmaceuticals by 314.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 20,546 shares of the biotechnology company's stock worth $174,000 after buying an additional 15,591 shares during the last quarter. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.